Literature DB >> 25399296

Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma.

Hongliang Liu1, Wei Liu, Bin Zhu, Qiang Xu, Xiaowei Ni, Ji Yu.   

Abstract

The LHX genes play a substantial role in an amount of adorning processes. Potential roles of LHXs have been accepted and approved in an assortment of neoplastic tissues as bump suppressors or promoters depending on bump cachet and types. The aim of this abstraction was to investigate the action role of LHXs in the animal High-grade Oligodendroglioma (HG-OT). The gene announcement changes of LHXs in HG-OT tissues compared with non-cancerous colorectal tissues were detected using application real-time quantitative about-face transcriptase-polymerase alternation acknowledgment (QRT-PCR) assay and immunohistochemistry. And we articulate the gene LHX3 that was decidedly up-regulated in HG-OT by QRT-PCR assay and immunohistochemistry. Furthermore, it was obvious that LHX3 responds to blight corpuscle admeasurement in vitro and LHX3 announcement activated with animated β-catenin levels in HG-OT and β-catenin action was appropriate for LHX3's oncogenic effects.  Mechanistically, LHX3 facilitates TCF4 to bind to β-catenin and facilitates LHX3/TCF4/β-catenin circuitous and trans-active it's after ambition gene. LHX3 mutations that agitate the LHX3-β-catenin alternation partially anticipate its action in bump cells. All in all, LHX3 is a frequently activated bump apostle that actuates Wnt/β-catenin signaling in blight beef of HG-OT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25399296     DOI: 10.1007/s11010-014-2209-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  18 in total

Review 1.  Molecular genetics of colorectal cancer.

Authors:  Eric R Fearon
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

Review 2.  Back to basics: Sox genes.

Authors:  Julie C Kiefer
Journal:  Dev Dyn       Date:  2007-08       Impact factor: 3.780

3.  Specification of pituitary cell lineages by the LIM homeobox gene Lhx3.

Authors:  H Z Sheng; A B Zhadanov; B Mosinger; T Fujii; S Bertuzzi; A Grinberg; E J Lee; S P Huang; K A Mahon; H Westphal
Journal:  Science       Date:  1996-05-17       Impact factor: 47.728

Review 4.  Wnt/beta-catenin signaling in oral tissue development and disease.

Authors:  F Liu; S E Millar
Journal:  J Dent Res       Date:  2010-03-03       Impact factor: 6.116

5.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Authors:  Y Ino; R A Betensky; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; D A Ramsay; J G Cairncross; D N Louis
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

6.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

Authors:  S W Coons; P C Johnson; B W Scheithauer; A J Yates; D K Pearl
Journal:  Cancer       Date:  1997-04-01       Impact factor: 6.860

Review 7.  Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease.

Authors:  Jay D Kormish; Débora Sinner; Aaron M Zorn
Journal:  Dev Dyn       Date:  2010-01       Impact factor: 3.780

8.  Successful chemotherapy for recurrent malignant oligodendroglioma.

Authors:  J G Cairncross; D R Macdonald
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

9.  An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells.

Authors:  Anna Bafico; Guizhong Liu; Luba Goldin; Violaine Harris; Stuart A Aaronson
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

10.  The temporal order of genetic and pathway alterations in tumorigenesis.

Authors:  Moritz Gerstung; Nicholas Eriksson; Jimmy Lin; Bert Vogelstein; Niko Beerenwinkel
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

View more
  1 in total

1.  LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling.

Authors:  Qiang Wang; Jinrong Liao; Zhiyong He; Ying Su; Dong Lin; Ling Xu; Haipeng Xu; Jinghui Lin
Journal:  Onco Targets Ther       Date:  2020-10-28       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.